Skip to main content

Table 1 Patient survival, graft survival and renal function with and without imputation for missing values at 12 and 24 months after conversion to belatacept. GFR 9 mL/min was imputed for kidney graft loss

From: Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept

  Switch to belatacept
(N = 30)
GFR at switch = 22.5 ± 12 mL/min
Control cohort
(N = 56)
GFR at start of observation = 24.5 ± 14 mL/min
Timepoint after switch 12 months 24 months 12 months 24 months
Patient survival 96.7% (29/30) 90% (27/30) 96.4% (54/56) 91.07% (51/56)
Death with functioning graft 1/30 3/30 2/56 5/56
Kidney or pancreas graft loss 6/30 9/30 8/56 16/56
Death-censored kidney graft survival 79.3% (23/29) 66.7% (18/27) 85.2% (46/54) 68.6% (35/51)
Overall kidney graft survival 76.7% (23/30) 60.0% (18/30) 82.1% (46/56) 62.5% (35/56)
Median GFR in patients without graft loss 23.3 ± 15 24.5 ± 15.0 23.0 ± 15 24.0 ± 9
ΔGFR from GFR at baseline in patients without graft loss 1.3 ± 5.9 1.8 ± 7.9 −2.0 ± 7.2 − 3.5 ± 8.6
Median GFR with imputation for graft loss 21.5 ± 18 18.5 ± 21 21.5 ± 18 19 ± 17
ΔGFR from GFR at baseline in patients with imputation for graft loss −0.56 ± 6.8 − 1.54 ± 8.4 −3.3 ± 7.6 −5.5 ± 8.3
  1. Data were expressed as medians (interquartile range), means (standard deviation) or numbers
  2. GFR glomerular filtration rate